The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma possess an aggressive disease etiology that usually commences with the enlargement of lymph node and progress to metastasis to other organs such as bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapy drug treatment and so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better drug efficacy and safety e.g. Zydelig, Gazyva, Abemaciclib and KTE-C19.
To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton;s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.
Country cross sectional market estimate and forecast for the geography segment has been included in the scope of the report.
The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.
Simulation-based medical training efficiently offers training to medical professionals for performing critical procedures on an interactive platform. This also assists surgeons and medical staff in improving clinical skills, emergency care delivery and augment safety outcomes. Patient simulation solutions offer high-fidelity equipment with features such as breathing pattern, sounds, pulse measurement, blood pressure monitoring, EKG and others. This market is driven by ethical sensitivity about patient subjects, and growing concerns on patient safety.
High-risk clinical departments such as intensive care, emergency response, anesthesia, neonatal care, and cath labs would most prominently benefit from adoption of mannequin-based simulation for training and education of healthcare personnel. This market may experience challenges in terms of restrained government funds.
Mannequin-based simulation finds the widest use in academics. Simulated medical training offers advantages such as safe training modules, hands-on education in interactive settings, and extensive training for emergency response. Challenges such as patient safety concerns are efficiently overcome through mannequin-based simulation tools such as high fidelity mannequins, patient safety virtual reality simulation and others. These solutions are being increasingly used in settings such as hospital rooms, emergency settings, and simulation facilities as training solutions and have demonstrated impressive results. Underutilization of simulation technologies due to complexity in assembly and operation had been a hindrance for growth in the past; however, it is being overcome by introduction of automated instruction and better user interfaces.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
To understand the drug regimen used for the treatment of mantle cell lymphoma the drugs segmented on the basis of mechanism of action are Bruton;s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus) and Proteasome Inhibitors (bortezomib). A brief description regarding the market size and forecast is available for the above segment.
Country cross sectional market estimate and forecast for the geography segment has been included in the scope of the report.
The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drug for the treatment of mantle cell lymphoma we need to cater competitive landscape. Latest merger or acquisition and purchase of promising drug molecules are mentioned in the company profile section. The major players in global mantle cell lymphoma treatment market are Celgene Corporation Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc. Johnson and Johnson and F.Hoffman La Roche Ltd.
Simulation-based medical training efficiently offers training to medical professionals for performing critical procedures on an interactive platform. This also assists surgeons and medical staff in improving clinical skills, emergency care delivery and augment safety outcomes. Patient simulation solutions offer high-fidelity equipment with features such as breathing pattern, sounds, pulse measurement, blood pressure monitoring, EKG and others. This market is driven by ethical sensitivity about patient subjects, and growing concerns on patient safety.
High-risk clinical departments such as intensive care, emergency response, anesthesia, neonatal care, and cath labs would most prominently benefit from adoption of mannequin-based simulation for training and education of healthcare personnel. This market may experience challenges in terms of restrained government funds.
Mannequin-based simulation finds the widest use in academics. Simulated medical training offers advantages such as safe training modules, hands-on education in interactive settings, and extensive training for emergency response. Challenges such as patient safety concerns are efficiently overcome through mannequin-based simulation tools such as high fidelity mannequins, patient safety virtual reality simulation and others. These solutions are being increasingly used in settings such as hospital rooms, emergency settings, and simulation facilities as training solutions and have demonstrated impressive results. Underutilization of simulation technologies due to complexity in assembly and operation had been a hindrance for growth in the past; however, it is being overcome by introduction of automated instruction and better user interfaces.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Mantle Cell Lymphoma Treatment market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Mantle Cell Lymphoma Treatment market and their expected impact during the forecast period.
Market Segmentation
Mechanism of Action
- Bruton;s Tyrosine Kinase Blocker (Ibrutinib)
- Angiogenesis Inhibitor (Lenalidomide)
- CD20 Antigen Inhibitor (Rituximab)
- mTOR Protein Inhibitor (Temsirolimus)
- Proteasome Inhibitors (Bortezomib)
- Phase III Drug
- Acalabrutinib
- Bendamustine/Rituximab/Ibrutinib (Qualitative Information)
- Ibrutinib/Venetoclax (Qualitative Information)
- Lenalidomide/Rituximab (Qualitative Information)
- Rituximab/Bortezomib (Qualitative Information)
- Tabular Representation of Phase II and I Drugs
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Mantle Cell Lymphoma Treatment market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Mantle Cell Lymphoma Treatment market?
- Which is the largest regional market for Mantle Cell Lymphoma Treatment market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Mantle Cell Lymphoma Treatment market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Mantle Cell Lymphoma Treatment market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Mantle Cell Lymphoma Treatment Market
2.2. Global Mantle Cell Lymphoma Treatment Market, By Mechanism of Action, 2021 (US$ Million)
2.3. Global Mantle Cell Lymphoma Treatment Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Mantle Cell Lymphoma Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Mantle Cell Lymphoma Treatment Market Vendors
3.2. Strategies Adopted by Mantle Cell Lymphoma Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Mantle Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Mantle Cell Lymphoma Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
5.3.2. Angiogenesis Inhibitor (Lenalidomide)
5.3.3. CD20 Antigen Inhibitor (Rituximab)
5.3.4. mTOR Protein Inhibitor (Temsirolimus)
5.3.5. Proteasome Inhibitors (Bortezomib)
5.3.6. Phase III Drug
5.3.6.1. Acalabrutinib
5.3.6.2. Bendamustine/Rituximab/Ibrutinib (Qualitative Information)
5.3.6.3. Ibrutinib/Venetoclax (Qualitative Information)
5.3.6.4. Lenalidomide/Rituximab (Qualitative Information)
5.3.6.5. Rituximab/Bortezomib (Qualitative Information)
5.3.7. Tabular Representation of Phase II and I Drugs
6. North America Mantle Cell Lymphoma Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
6.3.Mantle Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7. UK and European Union Mantle Cell Lymphoma Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.Mantle Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8. Asia Pacific Mantle Cell Lymphoma Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.Mantle Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
9. Latin America Mantle Cell Lymphoma Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
9.3.Mantle Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
10. Middle East and Africa Mantle Cell Lymphoma Treatment Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
10.3.Mantle Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Mantle Cell Lymphoma Treatment Market: By Mechanism of Action, 2020-2030, USD (Million)
11. Company Profile
11.1. Abbvie, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Amgen, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Astellas Pharma, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Biogen, Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Bayer AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Bristol-Myers Squibb Company
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Celgene Corporation
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. GlaxoSmithKline Plc
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Gilead Sciences, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Johnson and Johnson
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. F.Hoffman La Roche Ltd.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
List of Figures
Figure 1 Global Mantle Cell Lymphoma Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Mantle Cell Lymphoma Treatment Market: Quality Assurance
Figure 5 Global Mantle Cell Lymphoma Treatment Market, By Mechanism of Action, 2021
Figure 6 Global Mantle Cell Lymphoma Treatment Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Mantle Cell Lymphoma Treatment Market, 2021
Figure 8 Market Positioning of Key Mantle Cell Lymphoma Treatment Market Players, 2021
Figure 9 Global Mantle Cell Lymphoma Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Mantle Cell Lymphoma Treatment Market, By Mechanism of Action, 2021 Vs 2030, %
Figure 11 U.S. Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 12 Canada Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 14 UK Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 15 Germany Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 16 Spain Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 17 Italy Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 18 France Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 20 China Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 21 Japan Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 22 India Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 23 Australia Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 24 South Korea Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 26 Brazil Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 27 Mexico Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 29 GCC Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 30 Africa Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Mantle Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 2 Global Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 3 North America Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 4 North America Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 5 U.S. Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 6 U.S. Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 7 Canada Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 8 Canada Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 9 Rest of North America Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 10 Rest of North America Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 11 UK and European Union Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 12 UK and European Union Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 13 UK Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 14 UK Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 15 Germany Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 16 Germany Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 17 Spain Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 18 Spain Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 19 Italy Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 20 Italy Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 21 France Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 22 France Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 23 Rest of Europe Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 24 Rest of Europe Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 25 Asia Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 26 Asia Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 27 China Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 28 China Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 29 Japan Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 30 Japan Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 31 India Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 32 India Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 33 Australia Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 34 Australia Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 35 South Korea Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 36 South Korea Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 37 Latin America Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 38 Latin America Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 39 Brazil Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 40 Brazil Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 41 Mexico Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 42 Mexico Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 43 Rest of Latin America Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 44 Rest of Latin America Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 45 Middle East and Africa Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 46 Middle East and Africa Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 47 GCC Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 48 GCC Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 49 Africa Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 50 Africa Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Mantle Cell Lymphoma Treatment Market By Mechanism of Action, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Mantle Cell Lymphoma Treatment Market By Phase III Drug, 2020-2030, USD (Million)
Companies Mentioned
- Celgene Corporation Abbvie Inc.
- Astellas Pharma Inc.
- Biogen Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline Plc
- Amgen Inc.
- Gilead Sciences Inc.
- Johnson and Johnson
- F.Hoffman La Roche Ltd.
